Literature DB >> 23795928

Determination of artemether and dihydroartemisinin in human plasma with a new hydrogen peroxide stabilization method.

Liusheng Huang1, Alexander Olson, David Gingrich, Francesca T Aweeka.   

Abstract

BACKGROUND: Numerous methods have been reported for the determination of artemether (ARM) and its metabolite dihydroartemisinin (DHA) in plasma. However, stability issues in patient plasma have not received enough attention.
RESULTS: An LC-MS/MS method for simultaneous determination of ARM and DHA in human plasma (K3EDTA) turned out to be problematic: ARM and DHA were degraded partially or completely in some patient plasma samples as indicated by the stable isotope-labeled internal standards. We postulated iron II (Fe(2+)) in hemoglobin or its derived products from malaria patients causes degradation of the drugs, and found that hydrogen peroxide (H2O2) protected the drugs from degradation. Acidifying plasma increased recovery of ARM significantly. Using only 50 µl of plasma sample, the method has a LLOQ at 0.5 ng/ml for both ARM and DHA.
CONCLUSION: H2O2 is a stabilizing agent for artemisinin derivatives. The modified method is reliable and sensitive.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23795928      PMCID: PMC3879143          DOI: 10.4155/bio.13.91

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  10 in total

1.  Binding of artemether and lumefantrine to plasma proteins and erythrocytes.

Authors:  D Colussi; C Parisot; F Legay; G Lefèvre
Journal:  Eur J Pharm Sci       Date:  1999-10       Impact factor: 4.384

2.  Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma.

Authors:  C Souppart; N Gauducheau; N Sandrenan; F Richard
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-07-15       Impact factor: 3.205

3.  A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma.

Authors:  Warunee Hanpithakpong; Benjamas Kamanikom; Pratap Singhasivanon; Nicholas J White; Nicholas Pj Day; Niklas Lindegardh
Journal:  Bioanalysis       Date:  2009-04       Impact factor: 2.681

4.  A liquid-liquid LC/MS/MS assay for the determination of artemether and DHA in malaria patient samples.

Authors:  Lubbe Wiesner; Katya Govender; Sandra A Meredith; Jennifer Norman; Peter J Smith
Journal:  J Pharm Biomed Anal       Date:  2011-02-04       Impact factor: 3.935

5.  Heat stabilization of blood spot samples for determination of metabolically unstable drug compounds.

Authors:  Daniel Blessborn; Karl Sköld; David Zeeberg; Karnrawee Kaewkhao; Olof Sköld; Martin Ahnoff
Journal:  Bioanalysis       Date:  2013-01       Impact factor: 2.681

6.  Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies.

Authors:  N Lindegardh; W Hanpithakpong; B Kamanikom; P Singhasivanon; D Socheat; P Yi; A M Dondorp; R McGready; F Nosten; N J White; N P J Day
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-10-18       Impact factor: 3.205

7.  Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma.

Authors:  Liusheng Huang; Anura L Jayewardene; Xiaohua Li; Florence Marzan; Patricia S Lizak; Francesca T Aweeka
Journal:  J Pharm Biomed Anal       Date:  2009-07-07       Impact factor: 3.935

8.  Protein binding and alpha : beta anomer ratio of dihydroartemisinin in vivo.

Authors:  Kevin T Batty; Kenneth F Ilett; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

9.  A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma.

Authors:  E M Hodel; B Zanolari; T Mercier; J Biollaz; J Keiser; P Olliaro; B Genton; L A Decosterd
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-02-11       Impact factor: 3.205

10.  Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica.

Authors:  Jennifer Keiser; Marie-Stella Gruyer; Nancy Perrottet; Boris Zanolari; Thomas Mercier; Laurent Decosterd
Journal:  J Antimicrob Chemother       Date:  2009-01-24       Impact factor: 5.790

  10 in total
  9 in total

1.  Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Authors:  Meghan E Whalen; Richard Kajubi; Nona Chamankhah; Liusheng Huang; Francis Orukan; Erika Wallender; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan; Philip J Rosenthal; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

2.  Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.

Authors:  R Kajubi; L Huang; P Jagannathan; N Chamankhah; M Were; T Ruel; C A Koss; A Kakuru; N Mwebaza; M Kamya; D Havlir; G Dorsey; P J Rosenthal; F T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

3.  Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.

Authors:  Sunil Parikh; Fatai Fehintola; Liusheng Huang; Alexander Olson; Waheed A Adedeji; Kristin M Darin; Gene D Morse; Robert L Murphy; Babafemi O Taiwo; Olusegun O Akinyinka; Isaac F Adewole; Francesca T Aweeka; Kimberly K Scarsi
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.

Authors:  Emma Hughes; Norah Mwebaza; Liusheng Huang; Richard Kajubi; Vy Nguyen; Myaing M Nyunt; Francis Orukan; Moses W Mwima; Sunil Parikh; Francesca Aweeka
Journal:  J Acquir Immune Defic Syndr       Date:  2020-02-01       Impact factor: 3.771

5.  Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children.

Authors:  Richard Kajubi; Liusheng Huang; Moses Were; Sylvia Kiconco; Fangyong Li; Florence Marzan; David Gingrich; Myaing M Nyunt; Joshua Ssebuliba; Norah Mwebaza; Francesca T Aweeka; Sunil Parikh
Journal:  Open Forum Infect Dis       Date:  2016-12-15       Impact factor: 3.835

6.  Stability of the antimalarial drug dihydroartemisinin under physiologically relevant conditions: implications for clinical treatment and pharmacokinetic and in vitro assays.

Authors:  Silvia Parapini; Piero Olliaro; Visweswaran Navaratnam; Donatella Taramelli; Nicoletta Basilico
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

7.  Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.

Authors:  Myaing M Nyunt; Vy K Nguyen; Richard Kajubi; Liusheng Huang; Joshua Ssebuliba; Sylvia Kiconco; Moses W Mwima; Jane Achan; Francesca Aweeka; Sunil Parikh; Norah Mwebaza
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

8.  Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.

Authors:  Sunil Parikh; Richard Kajubi; Liusheng Huang; Joshua Ssebuliba; Sylvia Kiconco; Qin Gao; Fangyong Li; Moses Were; Abel Kakuru; Jane Achan; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Infect Dis       Date:  2016-05-03       Impact factor: 9.079

9.  Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

Authors:  Liusheng Huang; Vincent Carey; Jane C Lindsey; Florence Marzan; David Gingrich; Bobbie Graham; Linda Barlow-Mosha; Phionah K Ssemambo; Portia Kamthunzi; Sharon Nachman; Sunil Parikh; Francesca T Aweeka
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.